Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.68 |
| ▸ | NAMPT | P43490 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451018 | 1.00 | GPR119 (0.68) | GPR119NAMPTMEN1KMT2AMMP13 | |
| SCHEMBL22284240 | 0.94 | GPR119 (0.70) | GPR119NAMPTMEN1KMT2A | |
| SCHEMBL282240 | 0.83 | GPR119 (0.60) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL31511500 | 0.82 | GPR119 (0.53) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL4980907 | 0.81 | MEN1 (0.48) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL4973467 | 0.81 | MEN1 (0.48) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL29770088 | 0.81 | HTR7 (0.52) | GPR119MEN1KMT2A | |
| SCHEMBL28537628 | 0.81 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL28537559 | 0.81 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL28537557 | 0.81 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | GPR119 15/4885NAMPT 4040/4885MEN1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.